208 related articles for article (PubMed ID: 28298130)
1. Advanced APMs and the emerging role of immuno-oncology agents: balancing innovation and value.
Seiden MV; Neubauer M; Verrilli D
Am J Manag Care; 2017 Feb; 23(2 Spec No.):SP69-SP77. PubMed ID: 28298130
[No Abstract] [Full Text] [Related]
2. Customer pyramid framework for CAR T-cell therapies in immuno-oncology.
Malik NN; Durdy MB
Drug Discov Today; 2016 Oct; 21(10):1563-1565. PubMed ID: 27640934
[No Abstract] [Full Text] [Related]
3. Precision Medicine in Oncology II: Economics of Targeted Agents and Immuno-Oncology Drugs.
Huntington SF; Davidoff AJ; Gross CP
J Clin Oncol; 2020 Feb; 38(4):351-358. PubMed ID: 31804866
[No Abstract] [Full Text] [Related]
4. The promise of Immuno-oncology: implications for defining the value of cancer treatment.
Kaufman HL; Atkins MB; Subedi P; Wu J; Chambers J; Joseph Mattingly T; Campbell JD; Allen J; Ferris AE; Schilsky RL; Danielson D; Lichtenfeld JL; House L; Selig WKD
J Immunother Cancer; 2019 May; 7(1):129. PubMed ID: 31101066
[TBL] [Abstract][Full Text] [Related]
5. Why oncologists need technology to succeed in alternative payment models.
Fargnoli B; Holleran R; Kolodziej M
Am J Manag Care; 2017 Apr; 23(5 Spec No.):SP196-SP198. PubMed ID: 28665678
[No Abstract] [Full Text] [Related]
6. Targeted immunotherapies overtaking emerging oncology market value based growth.
Jakovljevic MB
J BUON; 2015; 20(1):350-1. PubMed ID: 25778340
[No Abstract] [Full Text] [Related]
7. Perspectives on the integration of Immuno-Oncology Biomarkers and drugs in a Health Care setting.
Vermaelen K; Waeytens A; Kholmanskikh O; Van den Bulcke M; Van Valckenborgh E
Semin Cancer Biol; 2018 Oct; 52(Pt 2):166-177. PubMed ID: 29170067
[TBL] [Abstract][Full Text] [Related]
8. The cost of treating cancer patients: treatments versus reimbursements.
Goldstein MG
Md Med; 2011; 12(4):15. PubMed ID: 22455202
[No Abstract] [Full Text] [Related]
9. Host immunity ignored in clinical oncology: a medical opinion.
Elliott RL; Head JF
Cancer Biother Radiopharm; 2005 Apr; 20(2):123-5. PubMed ID: 15869445
[No Abstract] [Full Text] [Related]
10. Squaring value-based payment with innovation in oncology.
Caffrey M
Am J Manag Care; 2018 Oct; 24(12 Spec No.):SP482-SP484. PubMed ID: 30550253
[No Abstract] [Full Text] [Related]
11. Desperation Oncology.
Fojo T
Semin Oncol; 2018 Jun; 45(3):105-106. PubMed ID: 30301565
[No Abstract] [Full Text] [Related]
12. Managing patient expectations with immuno-oncology.
Dangi-Garimella S
Am J Manag Care; 2017 Feb; 23(2 Spec No.):SP59. PubMed ID: 28298136
[No Abstract] [Full Text] [Related]
13. Making sense of advanced payment models.
McAneny B; Grubbs SS; Birch W; Sayam Zuckerman D
Am J Manag Care; 2017 Apr; 23(5 Spec No.):SP199-SP200. PubMed ID: 28665679
[No Abstract] [Full Text] [Related]
14. Introduction.
Reardon DA; Weller M
Neuro Oncol; 2015 Nov; 17 Suppl 7(Suppl 7):vii1. PubMed ID: 26516220
[No Abstract] [Full Text] [Related]
15. Models for Immuno-oncology Research.
Cancer Cell; 2020 Aug; 38(2):145-147. PubMed ID: 32781038
[TBL] [Abstract][Full Text] [Related]
16. Developing and validating model systems for immuno-oncology.
McCarthy CE; Zahir N; Eljanne M; Sharon E; Voest EE; Palucka K
Cancer Cell; 2021 Aug; 39(8):1018-1022. PubMed ID: 34115988
[TBL] [Abstract][Full Text] [Related]
17. Clinical development of immuno-oncology in China.
Wu DW; Huang HY; Tang Y; Zhao Y; Yang ZM; Wang J; Wang SH; Yu Y; Fang Y; Fang H; Bai Y; Sun C; Fan Q; Yu AQ; Wang HL; Du CX; Chen K; Huang MD; Zhang Y; Li N; Xu BH; Sun Y; He J
Lancet Oncol; 2020 Aug; 21(8):1013-1016. PubMed ID: 32758460
[No Abstract] [Full Text] [Related]
18. Value and payment for oncology in the United States.
Robinson JC
Ann Pharm Fr; 2013 Sep; 71(5):285-90. PubMed ID: 24075699
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy and the Interventional Oncologist: Challenges and Opportunities-A Society of Interventional Oncology White Paper.
Erinjeri JP; Fine GC; Adema GJ; Ahmed M; Chapiro J; den Brok M; Duran R; Hunt SJ; Johnson DT; Ricke J; Sze DY; Toskich BB; Wood BJ; Woodrum D; Goldberg SN
Radiology; 2019 Jul; 292(1):25-34. PubMed ID: 31012818
[TBL] [Abstract][Full Text] [Related]
20. First advanced course on biomarkers in molecular and immuno-oncology in the Middle East.
Moujaess E; Khoury M; Zouein J; Eid JB; Mohty R; Kourie HR
Future Oncol; 2021 Aug; 17(22):2831-2834. PubMed ID: 34148366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
